ClinicalTrials.gg
RecruitingNCT05957471BC3195Updated Jul 24, 2023

Study of BC3195 Monotherapy in Patients With Advanced Solid Tumors

A Phase 1 interventional study of Drug: BC3195 for Injection in Locally Advanced or Metastatic Solid Tumors, sponsored by Biocity Biopharmaceutics Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-07-24.

Sponsored by Biocity Biopharmaceutics Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jun 2025, 1 year 5 months ago, but the record still lists the study as recruiting.
  • Started Jun 2023; still recruiting 3 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
27
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This is a phase I study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Efficacy of BC3195 in Patients with Locally Advanced or Metastatic Solid Tumors.

Read the detailed description

This is a phase I study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Efficacy of BC3195 in Patients with Locally Advanced or Metastatic Solid Tumors.

The patients in whom standard treatment has failed (either due to disease progression or intolerance), who meet the criteria will receive BC3195 via intravenous (IV) in 21-day treatment cycles.

A Safety Monitoring Committee (SMC) will be established to decide the dose levels to be administered and dose regimen during dose escalation based on a thorough review of all the safety, PK (if applicable), and other relevant data from the previous dose cohort, and to determine the MTD and the putative RP2D for dose expansion.

02

Conditions studied

  • Locally Advanced or Metastatic Solid Tumors

Keywords

  • Solid Tumors
03

In context

Lead sponsor

Biocity Biopharmaceutics Co., Ltd. is the lead sponsor of 11 studies on the registry; 10 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients voluntarily participate in the study and should provide a written .
  2. Male or female patients ≥ 18 years of age.
  3. (ECOG) performance status of 0-1.
  4. Subjects with locally advanced or solid tumors failed to prior SOCs and no appropriate SOC to treat the current disease per investigator's judgement.
  5. ≥ 3 months.
  6. Subjects with adequate organ function.
  7. Men or women of (which refer to men or women who have not been surgically sterilized and pre-menopausal women) must use a highly effective method of during the study and continue to take contraception measures for 6 months after the last dose of the study drug.

Exclusion criteria

Exclusion Criteria:

  1. Pregnant or lactating women.
  2. Prior systemic anticancer treatment within 5 half-lives or 4 weeks before the first dose (whichever is shorter).
  3. Active viral infection requiring systemic therapy during the screening period.
  4. Hypertension that cannot be well-controlled with medical treatment.
  5. Cardiovascular disease of clinical significance.
  6. Subjects with any active infection that requires anti-infective therapy judged by the investigators.
  7. Subjects are not suitable for participating the study judged by the investigators.
  8. Subjects with poor compliance, who are unwilling to or unable to follow study procedures.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
27 participants (estimated)

Study arms

  • Experimental
    BC3195 treatment group.

    BC3195 via intravenous(IV).

    Drug: Drug: BC3195 for Injection

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of dose limiting toxicities (DLTs) .

    Time frame: Dose limiting toxicities (DLT) will be assessed At the end of Cycle 1 (each cycle is 21 days).

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2023 (actual). Primary completion is estimated for Jun 2025, 24 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 13, 2023
First posted
Jul 24, 2023
StartActual
Jun 26, 2023
Primary completionEst.
Jun 2025
CompletionEst.
Jun 2025
Last update
Jul 24, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 24, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05957471
Lead sponsor
Biocity Biopharmaceutics Co., Ltd.
Responsible party
Sponsor
First posted
Jul 24, 2023
Start date
Jun 26, 2023
Primary completion
Jun 2025 (estimated)
Completion
Jun 2025 (estimated)
Last update
Jul 24, 2023

Study contacts

Yilong Wu
Contact
syylwu@live.cn
021-38804518 ext. 22132
Huajun Chen
Contact
chenhuajun@gdph.org.cn
021-38804518 ext. 22132

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-CDH3/MMAE Antibody-drug Conjugate BC3195

Start the discussion